Sweden's Bactiguard Q4 revenue beats estimates

Bactiguard Holding AB

05/02/2026 06:13

Overview

Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted

Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln

Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln

Outlook

Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026

Company plans to secure additional partnerships and support existing partners in 2026

Bactiguard to enhance operational efficiency to support growth and profitability

Result Drivers

ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business

HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas

CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
SEK 65.60 mln
SEK 51 mln (1 Analyst)
Q4 Adjusted EPS
SEK 0.36
Q4 Net Income
SEK 12.50 mln
Q4 EBITDA
SEK 24.70 mln
Q4 Operating Cash Flow
SEK 11.70 mln
Q4 Operating Profit
SEK 13 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85

Press Release: ID:nWkrbhS21N

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)